- Affiliate Professor, Global Health
Fred Hutchinson Cancer Research Center
1100 Fairview Ave N
Seattle, WA 98109
Select from the following:
Our Group investigates the development of protective antibody responses during viral infections, with emphasis on HIV-1 and SARS-CoV-2, by employing diverse immunological, cellular and molecular high-throughput platforms. Immunogens to target specific B cell lineages are designed using structural and modeling approaches and the immune responses they elicit are characterized in detail.
- PhD (McGill University (Canada))
- MS (University of Paris VI (France))
- BS (University of Paris (France))
- Host-Pathogen Interactions
- Infectious Diseases
- CFAR: Immunology Core
- Consortia for HIV/AIDS Vaccine Development
- Defining BCR evolution during Immunization
- Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens
- Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs
- Immune Responses to Malaria and HIV Infection and Immunization
- Monitoring the development of anti-Env Abs during HIV-infection
- Neutralizing and non-neutralizing antibody effector functions in HIV infected children
Parks, K.R., A. J. MacCamy, J. Trichka, M. Gray, C. Weidle, A. Borst, A. Khechaduri, B. Takushi, P. Agrawal, J. Guenaga, R. T. Wyatt, R. Coler, C. LaBranche, D. C. Montefiori, D. Veesler, M. Pancera, A. McGuire and L. Stamatatos. 2019. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Reports. 29; 3060-3072.
Seydoux, E., L. J. Homad, A. J. MacCamy, K. R. Parks, N. K. Hurlburt, M. F. Jennewein, N. R. Akins, A. B. Stuart, Y-H. Wan, J. Feng, R. E. Whaley, S. Singh, M. Boeckh, K. W. Cohen, M. J. McElrath, J. A. Englund, H. Y. Chu, M. Pancera, A. T. McGuire and L. Stamatatos. 2020. Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 53; 98-105.
Lin, Y. -R., K. R. Parks, C. Weidle, A. S. Naidu, A. Khechaduri, A. Riker, B. Takushi, J.-H. Chun, A. Stuart, P. Agrawal, M. Gray, M. Pancera, P.-S. Huang and L. Stamatatos. 2020. HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. Immunity. 53; 840-851.
Stamatatos, L., J. Czartoski, Y-H. Wan, L. J. Homad, V. Rubin, H. Glantz, M. Neradilek, E. Seydoux, M. F. Jennewein, A. J. MacCamy, J. Feng, G. Mize, S. C. De Rosa, A. Finzi, M. P. Lemos, K. W. Cohen, Z. Moodie, M. J. McElrath, A. T. McGuire. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021. Science. 372; 1413–1418, eabg9175.
Jennewein, M.F., A. J. MacCamy, N. R. Akins, J. Feng, L. J. Homad, N. K. Hurlburt, E. Seydoux, Y.-H. Wan, A. B. Stuart, V. V. Edara, K. Floyd, A. Vanderheiden, J. R. Mascola, N. Doria-Rose, L. Wang, E. S. Yang, H. Y. Chu, J. L. Torres, G. Ozorowski, A. B. Ward, R. E. Whaley, K. W. Cohen, M. Pancera, M. J. McElrath, J. A. Englund, A. Finzi, M. S. Suthar, A. T. McGuire, L. Stamatatos. 2021. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. Cell Reports. 36; 109353